These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 8990820)

  • 21. Risperidone for the treatment of behavioral and psychological symptoms of dementia.
    Tune LE
    J Clin Psychiatry; 2001; 62 Suppl 21():29-32. PubMed ID: 11584986
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Utilisation of atypical antipsychotic drugs in institutionalised elderly persons and prevalence of metabolic alterations].
    Martínez Romero G; Peris Martí JF; Gomar Fayos J; Navarro Gosalbez M; Quintana Vargas I; Muelas Tirado J
    Farm Hosp; 2010; 34(3):139-47. PubMed ID: 20434929
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Switching from depot antipsychotics to risperidone: results of a study of chronic schizophrenia. The Schizophrenia Treatment & Assessment Group.
    Desai NM; Huq Z; Martin SD; McDonald G
    Adv Ther; 1999; 16(2):78-88. PubMed ID: 10539380
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics.
    Lindenmayer JP; Eerdekens E; Berry SA; Eerdekens M
    J Clin Psychiatry; 2004 Aug; 65(8):1084-9. PubMed ID: 15323593
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The dyskinesia Identification System Condensed User Scale (DISCUS): reliability, validity, and a total score cut-off for mentally ill and mentally retarded populations.
    Kalachnik JE; Sprague RL
    J Clin Psychol; 1993 Mar; 49(2):177-89. PubMed ID: 8098048
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rational use and rationale for use: psychiatric medication at an Argentine institution for intellectual disability.
    de Menil V; Cohen A
    Transcult Psychiatry; 2009 Dec; 46(4):651-71. PubMed ID: 20028682
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risperidone and withdrawal dyskinesia.
    Lore C
    J Am Acad Child Adolesc Psychiatry; 2000 Aug; 39(8):941. PubMed ID: 10939219
    [No Abstract]   [Full Text] [Related]  

  • 28. Dose-dependent effect of risperidone treatment in a case of 22q13.3 deletion syndrome.
    Pasini A; D'Agati E; Casarelli L; Curatolo P
    Brain Dev; 2010 May; 32(5):425-7. PubMed ID: 19428206
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Risperidone and tardive dyskinesia in organic psychosis.
    Fischer P; Tauscher J; Küfferle B
    Pharmacopsychiatry; 1998 Mar; 31(2):70-1. PubMed ID: 9562212
    [No Abstract]   [Full Text] [Related]  

  • 30. Chorea and tardive dyskinesia in a patient taking risperidone.
    Carroll NB; Boehm KE; Strickland RT
    J Clin Psychiatry; 1999 Jul; 60(7):485-7. PubMed ID: 10453805
    [No Abstract]   [Full Text] [Related]  

  • 31. Case study of neuroleptic-induced akathisia: important implications for individuals with mental retardation.
    Gross EJ; Hull HG; Lytton GJ; Hill JA; Piersel WC
    Am J Ment Retard; 1993 Jul; 98(1):156-64. PubMed ID: 8103997
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Risperidone treatment of behavioral disturbances in outpatients with dementia.
    Irizarry MC; Ghaemi SN; Lee-Cherry ER; Gomez-Isla T; Binetti G; Hyman BT; Growdon JH
    J Neuropsychiatry Clin Neurosci; 1999; 11(3):336-42. PubMed ID: 10440009
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Factors associated with the successful or unsuccessful withdrawal of antipsychotic drug therapy prescribed for people with learning disabilities.
    Branford D
    J Intellect Disabil Res; 1996 Aug; 40 ( Pt 4)():322-9. PubMed ID: 8884587
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of risperidone for behavioral disorders in the elderly: a clinical observation.
    Raheja RK; Bharwani I; Penetrante AE
    J Geriatr Psychiatry Neurol; 1995 Jul; 8(3):159-61. PubMed ID: 7576039
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Benzodiazepine behavioral side effects: review and implications for individuals with mental retardation.
    Kalachnik JE; Hanzel TE; Sevenich R; Harder SR
    Am J Ment Retard; 2002 Sep; 107(5):376-410. PubMed ID: 12186578
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discontinuation of neuroleptics in community-dwelling individuals with mental retardation and mental illness.
    Pary RJ
    Am J Ment Retard; 1995 Sep; 100(2):207-12. PubMed ID: 8527116
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neuroleptic malignant syndrome and mental retardation: review and analysis of 29 cases.
    Boyd RD
    Am J Ment Retard; 1993 Jul; 98(1):143-55. PubMed ID: 8103996
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Posthallucinogen-like visual illusions (palinopsia) with risperidone in a patient without previous hallucinogen exposure: possible relation to serotonin 5HT2a receptor blockade.
    Lauterbach EC; Abdelhamid A; Annandale JB
    Pharmacopsychiatry; 2000 Jan; 33(1):38-41. PubMed ID: 10721882
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Late dyskinesias in treatment with neuroleptics].
    Grecu G; Szücs K; Aşgian B; Grecu Căreanu M
    Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Neurol Psihiatr Neurochir; 1982; 27(4):249-59. PubMed ID: 6134327
    [No Abstract]   [Full Text] [Related]  

  • 40. Behavioral interactions induced by chronic neuroleptic therapy in persons with mental retardation.
    Schroeder SR; Gualtieri CT
    Psychopharmacol Bull; 1985; 21(2):310-5. PubMed ID: 2860695
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.